Literature DB >> 7914822

Lower extremity stress fractures during intermittent cyclical etidronate treatment for osteoporosis.

N Guañabens1, P Peris, A Monegal, F Pons, A Collado, J Muñoz-Gómez.   

Abstract

During intermittent cyclical etidronate treatment, a lower extremity pain syndrome associated with stress fractures was observed in three osteoporotic patients. This report describes the development of stress fractures during initial cycles of treatment, with recurrence of symptoms in two patients when etidronate therapy was resumed. Further studies are needed to confirm whether stress fractures are associated with cyclic etidronate treatment and if so, the incidence and pathophysiology need to be determined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914822     DOI: 10.1007/bf00305532

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

1.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

Authors:  T Storm; G Thamsborg; T Steiniche; H K Genant; O H Sørensen
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

2.  Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate.

Authors:  C J Gibbs; J E Aaron; M Peacock
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-10

3.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

Authors:  N B Watts; S T Harris; H K Genant; R D Wasnich; P D Miller; R D Jackson; A A Licata; P Ross; G C Woodson; M J Yanover
Journal:  N Engl J Med       Date:  1990-07-12       Impact factor: 91.245

4.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

5.  Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.

Authors:  T Storm; T Steiniche; G Thamsborg; F Melsen
Journal:  J Bone Miner Res       Date:  1993-02       Impact factor: 6.741

6.  Skeletal scintigraphic changes in osteoporosis treated with sodium fluoride: concise communication.

Authors:  E E Schulz; C R Libanati; S M Farley; G A Kirk; D J Baylink
Journal:  J Nucl Med       Date:  1984-06       Impact factor: 10.057

7.  Mechanism of acute lower extremity pain syndrome in fluoride-treated osteoporotic patients.

Authors:  J D O'Duffy; H W Wahner; W M O'Fallon; K A Johnson; J M Muhs; J W Beabout; S F Hodgson; B L Riggs
Journal:  Am J Med       Date:  1986-04       Impact factor: 4.965

8.  Trabecular stress fractures during fluoride therapy for osteoporosis.

Authors:  C M Schnitzler; L Solomon
Journal:  Skeletal Radiol       Date:  1985       Impact factor: 2.199

  8 in total
  3 in total

Review 1.  Pharmacogenetics of osteoporosis: what is the evidence?

Authors:  Francesca Marini; Maria Luisa Brandi
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

2.  Is the metatarsal fracture in postmenopausal women an osteoporotic fracture? A cross-sectional study on 113 cases.

Authors:  M Varenna; L Binelli; F Zucchi; P Beltrametti; M Gallazzi; L Sinigaglia
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 3.  Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

Authors:  R Rizzoli; K Akesson; M Bouxsein; J A Kanis; N Napoli; S Papapoulos; J-Y Reginster; C Cooper
Journal:  Osteoporos Int       Date:  2010-11-18       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.